EFFECTIVENESS OF SHORT TERM NEOADJUVANT ENDOCRINE THERAPY ON KI67 IN LUMINAL BREAST CANCERS

被引：0
|
作者：
Louis, D. [1 ]
Surendran, H. [1 ]
机构：
[1] Amrita Vishwa Vidyapeetham, Kochi, KL, India
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO102
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [21] Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers
    Satoshi Hayashi
    Masahiro Kitada
    Kazuhiro Sato
    Yoshinari Matsuda
    Kei Ishibashi
    Kensuke Oikawa
    Naoyuki Miyokawa
    Satoshi Hirata
    Breast Cancer, 2014, 21 : 47 - 51
  • [22] Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer
    Rocca, Andrea
    Farolfi, Alberto
    Maltoni, Roberta
    Carretta, Elisa
    Melegari, Elisabetta
    Ferrario, Cristiano
    Cecconetto, Lorenzo
    Sarti, Samanta
    Schirone, Alessio
    Fedeli, Anna
    Andreis, Daniele
    Pietri, Elisabetta
    Ibrahim, Toni
    Montalto, Erika
    Amadori, Dino
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (01) : 57 - 65
  • [23] Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
    von Minckwitz, Gunter
    Schmitt, Wolfgang D.
    Loibl, Sibylle
    Mueller, Berit M.
    Blohmer, Jens U.
    Sinn, Bruno V.
    Eidtmann, Holger
    Eiermann, Wolfgang
    Gerber, Bernd
    Tesch, Hans
    Hilfrich, Joern
    Huober, Jens
    Fehm, Tanja
    Barinoff, Jana
    Ruediger, Thomas
    Erbstoesser, Erhard
    Fasching, Peter A.
    Karn, Thomas
    Mueller, Volkmar
    Jackisch, Christian
    Denkert, Carsten
    CLINICAL CANCER RESEARCH, 2013, 19 (16) : 4521 - 4531
  • [24] Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer
    Andrea Rocca
    Alberto Farolfi
    Roberta Maltoni
    Elisa Carretta
    Elisabetta Melegari
    Cristiano Ferrario
    Lorenzo Cecconetto
    Samanta Sarti
    Alessio Schirone
    Anna Fedeli
    Daniele Andreis
    Elisabetta Pietri
    Toni Ibrahim
    Erika Montalto
    Dino Amadori
    Breast Cancer Research and Treatment, 2015, 152 : 57 - 65
  • [25] Predicting Outcome with Ki67 in Primary Breast Cancer in the Neoadjuvant Setting
    Li, S. P.
    Burcombe, R.
    Beresford, M. J.
    Kornbrot, D. E.
    Seah, M-L
    Ostler, P. J.
    Wilson, G. D.
    Makris, A.
    CANCER RESEARCH, 2010, 70
  • [26] Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
    da Silva, Leonardo Roberto
    Vargas, Renato Flora
    Shinzato, Julia Yoriko
    Mauricette Derchain, Sophie Francoise
    Ramalho, Susana
    Zeferino, Luiz Carlos
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2019, 41 (12): : 710 - 717
  • [27] Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2-translational results
    Grote, I.
    Bartels, S.
    Kandt, L.
    Bollmann, L.
    Christgen, H.
    Gronewold, M.
    Gluz, O.
    Nitz, U.
    Kuemmel, S.
    Braun, M.
    Aktas, B.
    Grischke, E-M.
    Schumacher, C.
    Luedtke-Heckenkamp, K.
    Kates, R.
    Wuerstlein, R.
    Graeser, M.
    Harbeck, N.
    Christgen, M.
    Kreipe, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S306 - S306
  • [28] Response letter to: Questions about Ki67 staining in luminal breast cancer
    Gallardo, Alberto
    Lerma, Enrique
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 601 - 601
  • [29] Response letter to: Questions about Ki67 staining in luminal breast cancer
    Alberto Gallardo
    Enrique Lerma
    Breast Cancer Research and Treatment, 2018, 167 : 601 - 601
  • [30] A FAST AND EASY EYEBALL METHOD TO CLASSIFY LUMINAL-TYPE BREAST CANCERS: NO MORE NEED TO COUNT KI67!
    Hida, A. I.
    Oshiro, Y.
    Kawaguchi, H.
    Inoue, H.
    Moriya, T.
    BREAST, 2013, 22 : S31 - S31
12345